Join

Compare · PACB vs RVTY

PACB vs RVTY

Side-by-side comparison of Pacific Biosciences of California Inc. (PACB) and Revvity Inc. (RVTY): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both PACB and RVTY operate in Biotechnology: Laboratory Analytical Instruments (Industrials), so they compete in similar markets.
  • RVTY is the larger of the two at $9.69B, about 19.5x PACB ($496.8M).
  • Over the past year, PACB is up 40.4% and RVTY is down 7.8% - PACB leads by 48.1 points.
  • RVTY has been more active in the news (7 items in the past 4 weeks vs 6 for PACB).
  • PACB has more recent analyst coverage (24 ratings vs 18 for RVTY).
PerformancePACB+40.35%RVTY-7.79%
2025-05-02+0.00%2026-05-01
MetricPACBRVTY
Company
Pacific Biosciences of California Inc.
Revvity Inc.
Price
$1.60+0.63%
$86.69+0.03%
Market cap
$496.8M
$9.69B
1M return
+19.40%
-1.41%
1Y return
+40.35%
-7.79%
Industry
Biotechnology: Laboratory Analytical Instruments
Biotechnology: Laboratory Analytical Instruments
Exchange
NASDAQ
NYSE
IPO
2010
News (4w)
6
7
Recent ratings
24
18
PACB

Pacific Biosciences of California Inc.

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing systems to resolve genetically complex problems. The company provides PacBio's Systems, which conduct, monitor, and analyse biochemical sequencing reactions; consumable products, including single molecule real-time (SMRT) cells; and various reagent kits designed for specific workflow, such as template preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. The company serves research institutions; commercial laboratories; genome centers; clinical, government, and academic institutions; genomics service providers; pharmaceutical companies; and agricultural companies. It markets its products through a direct sales force in North America and Europe, as well as through distribution partners in Asia, Europe, the Middle East, Africa, and Latin America. Pacific Biosciences of California, Inc. has a collaboration with Invitae Corporation to develop ultra-high-throughput clinical whole genome sequencing platform; and a research collaboration with Rady Children's Institute for Genomic Medicine for whole genome sequencing platform. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.